白细胞介素21
嵌合抗原受体
淋巴因子激活杀伤细胞
NK-92
白细胞介素12
Janus激酶3
细胞疗法
生物
抗原
受体
医学
免疫学
细胞生物学
自然杀伤细胞
免疫疗法
抗体
免疫系统
干细胞
T细胞
细胞毒性T细胞
体外
生物化学
作者
Ryan Golden,Andrew D. Fesnak
标识
DOI:10.1016/j.transci.2021.103065
摘要
Abstract
Both natural killer (NK) cells and T cells demonstrate potent antitumor responses in many settings. NK cells, unlike T cells, are not the primary mediators of graft-versus-host disease (GVHD). Redirection of T cells with chimeric antigen receptors (CAR) has helped to overcome tumor escape from endogenous T cells. NK cells expressing CARs are a promising new therapy to treat malignancy. Clinical biomanufacturing of CAR NK cells can begin with NK cells derived from many different sources including adult peripheral blood-derived NK cells, cord blood-derived NK cells, cell line-derived NK cells, or stem cell-derived NK cells. Manufacturing protocols may include isolation of NK cells, activation, expansion, and genetic modification to express the chimeric antigen receptors. Clinical trials have tested both unmodified and CAR NK cells with encouraging results. The next stage in clinical development of CAR NK cells represents a highly exciting new frontier in clinical cell therapy as well as understanding basic NK cell biology. The purpose of this review is to provide the reader with a fundamental understanding of the core concepts in CAR NK cell manufacturing, specifically highlighting differences between CAR T cell manufacturing and focusing on future directions in the field.
科研通智能强力驱动
Strongly Powered by AbleSci AI